Chinese firm launches phase-3 trial of Covid-19 vaccine in UAE: Report
This is the first company in China to conduct an overseas clinical trial of the Covid-19 vaccine, state broadcaster CGTN reported
)
Explore Business Standard
This is the first company in China to conduct an overseas clinical trial of the Covid-19 vaccine, state broadcaster CGTN reported
)
China's inactivated Covid-19 vaccine candidate has entered the phase-3 clinical trial in the United Arab Emirates, according to Sinopharm's China National Biotec Group (CNBG) on Tuesday.
This is the first company in China to conduct an overseas clinical trial of the Covid-19 vaccine, state broadcaster CGTN reported.
The vaccine, developed by the Wuhan Institute of Biological Products under CNBG affiliated to Sinopharm, has shown promising results in terms of both safety and efficacy in phase-1 and phase-2 clinical trials.
The CNBG is actively promoting overseas cooperation in the phase-3 clinical trial of the vaccine.
The is primarily because there are currently not enough Covid-19 patients in China required for a phase-3 clinical trial, according to experts.
The company has already secured the intention of cooperation of several firms and research institutions from different countries.
Already subscribed? Log in
Subscribe to read the full story →
3 Months
₹300/Month
1 Year
₹225/Month
2 Years
₹162/Month
Renews automatically, cancel anytime
Over 30 premium stories daily, handpicked by our editors


News, Games, Cooking, Audio, Wirecutter & The Athletic
Digital replica of our daily newspaper — with options to read, save, and share


Insights on markets, finance, politics, tech, and more delivered to your inbox
In-depth market analysis & insights with access to The Smart Investor


Repository of articles and publications dating back to 1997
Uninterrupted reading experience with no advertisements


Access Business Standard across devices — mobile, tablet, or PC, via web or app
First Published: Jun 24 2020 | 9:06 AM IST